rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Among brain tumors, the BRAF (V600E) mutation is frequently associated with pleomorphic xanthoastrocytomas (PXAs) and gangliogliomas (GGs).
|
26264609 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Among brain tumors, the BRAF (V600E) mutation is frequently associated with pleomorphic xanthoastrocytomas (PXAs) and gangliogliomas (GGs).
|
26264609 |
2015 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
An activating mutation of BRAF (BRAF-V600E) has been reported in a subset of malignant brain tumors.
|
24721513 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
An activating mutation of BRAF (BRAF-V600E) has been reported in a subset of malignant brain tumors.
|
24721513 |
2014 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing.
|
25346165 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing.
|
25346165 |
2015 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.
|
24823863 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.
|
24823863 |
2014 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF V600E-mutations have been described in a modest 6% to 7% of primary central nervous system (CNS) tumors, but with increased prevalence in the pediatric population and in certain brain tumor subtypes.
|
24725538 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E-mutations have been described in a modest 6% to 7% of primary central nervous system (CNS) tumors, but with increased prevalence in the pediatric population and in certain brain tumor subtypes.
|
24725538 |
2014 |
rs113488022
|
|
T |
0.800 |
GeneticVariation |
CLINVAR |
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy.
|
22586120 |
2012 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Efficacy of BRAF V600E targeted therapies in brain tumors harboring the mutation has been shown in several case reports and is currently being studied in larger clinical trials.
|
29380516 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Efficacy of BRAF V600E targeted therapies in brain tumors harboring the mutation has been shown in several case reports and is currently being studied in larger clinical trials.
|
29380516 |
2018 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Emerging evidence support the effectiveness of targeted therapies for brain tumors with BRAF V600E mutation.
|
31345255 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Emerging evidence support the effectiveness of targeted therapies for brain tumors with BRAF V600E mutation.
|
31345255 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Epithelioid glioblastoma is a recognized glioblastoma variant, recently added to the World Health Organization brain tumor classification, with similar prognosis as the classic variant and B-Raf V600E mutations in 50% of the cases.
|
31258848 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Epithelioid glioblastoma is a recognized glioblastoma variant, recently added to the World Health Organization brain tumor classification, with similar prognosis as the classic variant and B-Raf V600E mutations in 50% of the cases.
|
31258848 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Future clinical trials should address whether BRAF (V600E) mutant brain tumor patients will benefit from BRAF (V600E)-directed targeted therapies.
|
21274720 |
2011 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Future clinical trials should address whether BRAF (V600E) mutant brain tumor patients will benefit from BRAF (V600E)-directed targeted therapies.
|
21274720 |
2011 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Future clinical trials should address whether BRAF V600E mutant brain tumour patients will benefit from BRAF V600E-directed targeted therapies.
|
24353007 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Future clinical trials should address whether BRAF V600E mutant brain tumour patients will benefit from BRAF V600E-directed targeted therapies.
|
24353007 |
2014 |
rs113488022
|
|
T |
0.800 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs121913338
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs397516896
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs397516896
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |